Top 10 Drug Warnings and Recalls of 2007

Suggested Articles

Doctors fear that the only drug approved to prevent preterm birth will no longer be available after an FDA advisory committees vote in October.

Stinging from a previous trial failure in 2016, AstraZeneca's Brilinta topped solo aspirin in slicing CV risks in heart attack and stroke patients.

As the drug pricing debate rolls on, biopharma lobbyists are staying busy. Very busy, in fact. PhRMA, for one, spent a record $29 million last year.